Avandia Plaintiffs’ Sur-Reply Affidavit Properly Excluded, 3rd Circuit Affirms

(February 16, 2016, 2:44 PM EST) -- PHILADELPHIA — A panel of the Third Circuit U.S. Court of Appeals on Feb. 12 affirmed a district court’s striking of a sur-reply in an Avandia case and its grant of defense summary judgment (In Re Avandia Marketing, Sales Practices and Products Liability Litigation, No. 15-2059, 3rd Cir.; 2016 U.S. App. LEXIS 2477).

(Schatz opinion available. Document #28-160218-015Z.)

In 2002, Linda Schatz was prescribed Avandia to help treat her type 2 diabetes. In 2007, manufacturer GlaxoSmithKline PLC (GSK) told doctors that women taking Avandia had an...
To view the full article, register now.